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Satish Arora, MD,* Pål A. Jenum, MD, PHD,† Pål Aukrust, MD, PHD,‡ Halvor Rollag, MD, PHD,†¶
Arne K. Andreassen, MD, PHD,* Svein Simonsen, MD, PHD,* Einar Gude, MD,*
Arnt E. Fiane, MD, PHD,§ Odd Geiran, MD, PHD,§¶ Lars Gullestad, MD, PHD*
Oslo, Norway
Objectives We evaluated the risk of mortality, development of cardiac allograft vasculopathy (CAV), and acute cellular rejec-
tion among Toxoplasma gondii (T. gondii) seropositive heart transplant (HTx) recipients and the 4 donor/recipient
seropairing groups.
Background Chronic T. gondii infection is known to trigger potentially adverse immunoregulatory changes, but the long-term
implication for HTx recipients has not been assessed previously.
Methods Frozen pre-HTx serum samples of 288 recipients and 246 donors were evaluated for T. gondii serostatus using
Platelia immunoglobulin G immunoassay. Patients had undergone prospective serotesting using alternative as-
says, and results determined by the 2 methods were compared. Data regarding mortality, CAV, and acute cellu-
lar rejection were available for all patients.
Results Overall, 211 recipients (73%) were seronegative and 77 (27%) were seropositive. In total, 82 recipients died, 76
developed CAV, and 82 had 1 or more episode of treated cellular rejection. Recipient seropositivity was associ-
ated with a significantly higher risk of all-cause (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1 to 3.4;
p  0.02) and CAV mortality (HR 4.4, 95% CI 1.3 to 15.6; p  0.02) and a higher risk of developing advanced
CAV (HR 2.7, 95% CI 1.2 to 5.8; p  0.01). Seropositivity did not influence the number of rejection episodes,
and donor/recipient seropairing was not a risk factor for any end point.
Conclusions T. gondii seropositivity among HTx recipients is associated with an increased risk of all-cause and CAV mortality
and of development of advanced CAV. This may be mediated via immunoregulatory changes triggered by
chronic T. gondii infection and needs to be explored further. (J Am Coll Cardiol 2007;50:1967–72)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.068v
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tong-term survival after heart transplantation (HTx) is
imited by the development of cardiac allograft vasculopathy
CAV), and chronic inflammation and immune activation
re likely to play an important pathogenic role (1). Potential
riggers for this response include persistent alloantigen-
ependent reactions, but chronic low-grade infection may
lso be involved and there has been considerable interest
egarding possible microbial triggers, such as cytomegalo-
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ccepted July 30, 2007.irus (CMV) infection (2). Toxoplasma gondii (T. gondii) is
lifelong infection, and, although acute infection has been
ecognized as a clinical problem in HTx recipients, the
iterature is virtually devoid of data regarding the implica-
ion of chronic infection and associated immunoregulatory
hanges for prognosis in HTx recipients.
Primary T. gondii infection is largely asymptomatic in
ealthy individuals, and chronic parasite latency is main-
ained by an adaptive T-cell response particularly involving
nterleukin (IL)-12–driven interferon (IFN)- responses
3). Although a balanced immune response is required to
ontrol T. gondii reactivation, it is increasingly appreci-
ted that an excessively vigorous response can lead to
athologic effects, including endothelial cell activation,
nd this may be particularly relevant in the setting of organ
ransplantation and immunosuppression (4). Therefore, we
xamined the association between recipient T. gondii sero-
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Toxoplasma Seropositivity and Heart Transplant November 13, 2007:1967–72positivity and mortality, develop-
ment of CAV, and acute cellular
rejection among HTx patients.
We also determined whether do-
nor and recipient T. gondii ser-
opairing was related to the occur-
rence of these end points.
Methods
Patient serologic testing. All
HTx donors and recipients at our
center have undergone routine
prospective evaluation for T.
gondii serostatus using commer-
cially available enzyme immuno-
assays (EIAs). These analyses
ere performed with different methods and different lot
umbers, and this could potentially result in diagnostic
naccuracy. Therefore, we retested serum samples of 288
ecipients who underwent HTx between January 1994 and
ecember 2005. The study protocol was approved by the
nstitutional review board.
Serum samples had been obtained within 24 h before
Tx (stored at20°C) and were tested using an established
mmunoglobulin (Ig)G EIA (Platelia Toxo IgG TMB,
io-Rad, Marnes-la-Coquette, France) with the same lot
umber. An EIA result of 6.0 IU/ml was used as a cutoff for
he diagnosis of T. gondii seropositivity, according to the
anufacturer’s instructions and previously published data
5). Donor serum samples were available for 246 of these
atients and were also retested using the same technique.
rophylaxis and immunosuppressive regime. All patients
eceived prophylactic treatment for Pneumocystis jirovecii
ith trimethoprim-sulfamethoxazole for the first 6 months
fter HTx. No alternative prophylactic strategies were used.
riple immunosuppressive therapy was given according to
ocal protocol, and no cytotoxic induction therapy was used.
efinition of end points. MORTALITY. Survival data was
btained on all patients using mortality information from
he Norwegian Population Register. Cause of death was
onsidered to be due to CAV based on 1 or more of the
ollowing: 1) clinical history, examination, and investigation
ndings consistent with the diagnosis of myocardial infarc-
ion/heart failure as cause of death in a patient known to
ave significant CAV; 2) sudden death occurring in a
atient known to have significant CAV; or 3) autopsy
ndings confirming CAV as cause of death.
ARDIAC ALLOGRAFT VASCULOPATHY. All patients had been
valuated annually by coronary angiography. The classification
sed by Costanzo et al. (6) was applied to grade the CAV as
ild, moderate, or severe on the basis of left main stem
nvolvement, primary vessel stenoses, and branch stenoses.
CUTE CELLULAR REJECTION. Results of endomyocardial
Abbreviations
and Acronyms
CAV  cardiac allograft
vasculopathy
CMV  cytomegalovirus
EIA  enzyme
immunoassay
HTx  heart transplant/
transplantation
IFN  interferon
IL  interleukin
R  recipient
T. gondii  Toxoplasma
gondiiiopsies performed during the first year after HTx were gbtained for all patients. Biopsies had been performed upon
linical indication and by protocol at the following intervals:
eekly the first 2 months after HTx, biweekly in the third
onth, and then after 6 and 12 months.
tatistical analysis. Analysis was performed with the SPSS
tatistical software (version 13.0, SPSS Inc., Chicago, Illi-
ois), and a 2-sided p value of 0.05 was considered to be
tatistically significant. Student t test was used for normally
istributed variables and the Mann-Whitney test for other
ariables. Categorical variables were compared using the
hi-square test. Separate Kaplan-Meier analyses with log-
ank test were performed for the end points mortality and
AV. When evaluating the latter end point, patients who
ad died without CAV development were considered to be
ensored cases. A secondary analysis was performed to assess
he relationship between seropositivity and CAV death, and
n this analysis deaths not due to CAV were considered to
e censored. Variables with a p value of 0.05 upon
nivariate analysis were included in the final multivariate
egression analysis with the forward stepwise method.
esults
aseline characteristics of the 288 patients are shown in
able 1. Serum testing with Platelia Toxo IgG found 211
atients (73%) to be T. gondii seronegative and 77 patients
27%) to be T. gondii seropositive at the time of HTx. Of
he 211 seronegative patients, 209 had also been diagnosed
s seronegative by the initially used assays, indicating a 99%
oncordance rate. Of the 77 recipients identified as sero-
ositive by Platelia Toxo IgG, 70 had been diagnosed as
eropositive by initial assays (91% concordance). There was
o significant differences in the immunosuppressive therapy
etween T. gondii seropositive and seronegative patients
Table 1).
Donor serum was available for 246 recipients, and 199
81%) were T. gondii seronegative and 47 (19%) seroposi-
ive. The 4 donor (D) and recipient (R) T. gondii seropair-
ng groups had the following frequencies: D/R: n 145
59%); D/R: n  36 (15%); D/R: n  54 (22%);
nd D/R: n  11 (4%). Recipients in the D/R
roup were potentially at risk of seroconversion after HTx,
ut analysis of post-HTx samples (collected from recipients
uring the first year after HTx) revealed only 1 case of
eroconversion. No patients developed acute toxoplasmosis
nfection during the follow-up period.
ecipient T. gondii seropositivity and mortality. Median
ollow-up time for mortality was 5.5 (range 0 to 13.0) years,
nd 82 patients (28%) died during this period. There were
1 (24%) and 31 (40%) deaths among T. gondii seronegative
nd seropositive recipients, respectively (p 0.018) (Fig. 1).
s shown, the survival curves started to diverge at approx-
mately 4 years after HTx, indicating a predominantly
igher risk of long-term mortality among seropositive
ecipients. The increased mortality observed among T.
ondii seropositive recipients was predominantly attribut-
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November 13, 2007:1967–72 Toxoplasma Seropositivity and Heart Transplantble to higher incidence of CAV mortality among this
roup (Table 2). Multivariate Cox regression analysis iden-
ified recipient T. gondii seropositivity as an independent
redictor of mortality beyond 1 year after HTx, with an
djusted hazard ratio (HR) of 1.9 (95% confidence interval
CI] 1.1 to 3.4; p 0.02) (Table 3). When considering only
AV mortality, recipient T. gondii seropositivity was an
ndependent risk factor with an adjusted HR of 4.4 (95% CI
.3 to 15.6; p  0.02) (Table 4).
onor T. gondii seropositivity and mortality. Of 246
Baseline Characteristics of the Study Populatio
Table 1 Baseline Characteristics of the Stu
Characteristic Overall
Demographics
Recipient age (yrs) 54 (14–68)
Male recipient 238 (83%)
Etiology for HTx
Ischemic heart disease 144 (50%)
Cardiomyopathy 101 (35%)
Other 43 (15%)
CMV serostatus
Recipient CMV seropositivity 203 (71%)
CMV mismatch (R/D) 61 (21%)
Immunosuppressive therapy
Cyclosporin 283 (98%)
Tacrolimus 5 (2%)
Prednisolone 279 (97%)
Azathioprine 181 (63%)
Mycophenalate mofetil† 78 (27%)
Cardiovascular medication*
Beta-blocker 22 (9%)
Calcium-channel blocker 70 (28%)
Angiotensin-converting enzyme
inhibitor/receptor antagonist
87 (34%)
Diuretic 67 (26%)
Statin* 165 (65%)
Cardiovascular risk factors†
Hypertension 166 (65%)
Diabetes mellitus 22 (9%)
Current smoker 50 (20%)
Biochemical and hemodynamic data*
Total cholesterol (mmol/l) 5.6 1.2
Serum creatinine (mol/l) 118 33.3
Pulmonary artery mean
pressure (mm Hg)
17.1 5.4
Pulmonary capillary wedge
pressure (mm Hg)
8.2 4.3
Cardiac index (l/min/m2) 2.9 0.56
Donor characteristics
Donor age (yrs) 36 (12–61)
Male donor 182 (63%)
Ischemic time (min) 175 (38–313)
Data are reported as mean  SD, median (range), or n (%), as app
alternative to azathioprine) from 2002 onward, and statin therapy w
regarding these variables was collected at 1 year after HTx, when a
Therefore, data for these variables was only available for recipients wit
CMV  cytomegalovirus; HTx  heart trasplant; R/D  receipient/donors, 199 (81%) were T. gondii seronegative and 47 (19%) dere seropositive. There were 60 (30%) and 13 (28%)
eaths in these 2 groups, respectively (p  0.74). When
onsidering donor and recipient seropairing status, there
ere 37 (26%), 7 (19%), 23 (43%), and 6 (55%) deaths in
/R, D/R, D/R, and D/R groups, respec-
ively. When using D/R as the reference group, higher
ortality was evident among both D/R and D/R
roups (p  0.04 and p  0.01, respectively). However,
hen comparing D/R with D/R, there was no
ignificant difference in mortality (p 0.10), indicating that
288)
pulation (n  288)
ecipient T. gondii
Seronegative
(n  211)*
Recipient T. gondii
Seropositive
(n  77)* p Value
53 (14–68) 56 (17–67) 0.01
172 (82%) 66 (86%) 0.41
104 (49%) 40 (52%) 0.69
78 (37%) 23 (30%) 0.26
29 (14%) 14 (18%) 0.35
145 (69%) 58 (75%) 0.28
47 (22%) 14 (18%) 0.45
207 (98%) 76 (99%) 0.73
4 (2%) 1 (1%) 0.73
203 (96%) 76 (99%) 0.28
130 (62%) 51 (66%) 0.47
61 (29%) 17 (22%) 0.25
15 (8%) 7 (10%) 0.54
52 (28%) 18 (27%) 0.90
60 (32%) 27 (40%) 0.21
51 (27%) 16 (24%) 0.60
123 (65%) 42 (63%) 0.69
118 (63%) 48 (72%) 0.19
15 (8%) 7 (10%) 0.54
36 (19%) 14 (21%) 0.76
5.6 1.2 5.8 1.3 0.41
114 30.7 127.1 38.3 0.02
17.1 5.5 17.5 5.3 0.66
8.1 4.3 8.6 4.2 0.36
2.9 0.58 2.9 0.53 0.51
35 (12–61) 38 (14–56) 0.21
128 (61%) 54 (70%) 0.14
175 (38–313) 174 (41–286) 0.39
. *Mycophenalate mofetil was first introduced at our center (as an
ablished as protocol in all HTx patients from 1997 onward. †Data
steady state” can be expected, allowing more accurate comparison.
al1 year (n 255, of which 188 T. gondii negative and 67 positive).
. gondii  Toxoplasma gondii.n (n 
dy Po
R
ropriate
as est
more “onor T. gondii status did not influence mortality. Multi-
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Toxoplasma Seropositivity and Heart Transplant November 13, 2007:1967–72ariate analysis with seropairing status and donor and
ecipient serostatus as 3 separate variables confirmed that
nly recipient T. gondii seropositivity was an independent
redictor of mortality (p  0.01).
. gondii seropositivity and CAV. Median follow-up time
or CAV was 3.9 (range 0 to 13.0) years, and 76 patients
26%) developed CAV. Kaplan-Meier analysis indicated
hat T. gondii seropositive recipients were not at signifi-
antly higher risk of earlier CAV development (p  0.10).
uring the study period, 20 recipients developed moderate
AV and 6 developed severe CAV. Among T. gondii
eropositive recipients, 12 patients (16%) developed
oderate/severe CAV compared with only 14 seronega-
Figure 1 Survival According to Recipient T. gondii
Serostatus at Time of Heart Transplantation
Toxoplasma gondii (T. gondii) seropositive recipients had a significantly higher
risk of all-cause mortality, and this was predominantly evident in the period
beyond 4 years after transplantation.
Causes of Death Among T. gondiiSeronegativ and Seropositive Recipients (n 
Table 2 Causes of Death Among T. gondiiSeronegative and Seropositive Reci
Cause of Death Overall
Acute rejection 17 (6%)
Graft failure 4 (1%)
Allograft vasculopathy 12 (5%)
Sudden death 11 (4%)
Acute infection 7 (2%)
Malignancy 16 (6%)
Other causes (neurologic, renal failure,
hemorrhage, respiratory failure,
multiple organ failure)
15 (5%)*Compared by Kaplan-Meier analysis with log rank test.
T. gondii  Toxoplasma gondii.ive recipients (7%; p  0.01) (Fig. 2). Multivariate
nalysis confirmed recipient T. gondii seropositivity as a
isk factor for development of advanced CAV, with an
djusted HR of 2.7 (95% CI 1.2 to 5.8; p  0.01). There
as no significant difference regarding CAV incidence or
rogression among the 4 D/R seropairing groups. Simi-
arly, statin therapy and CMV infection did not influence
he risk of CAV development or progression (data not
hown).
. gondii seropositivity and acute cellular rejection. Dur-
ng the first year after HTx, 19 T. gondii seropositive
ecipients (25%) had at least 1 episode of treated cellular
ejection (grade 2R or 3R) compared with 63 seronega-
ive recipients (30%; p  0.39). Similarly, 4 seropositive
ecipients (5%) had more than 1 episode of treated
ellular rejection compared with 13 seronegative recipi-
nts (6%; p  0.76). There were 3 (4%) and 11 (5%)
pisodes of vascular rejection among seropositive and
eronegative patients, respectively (p  0.65). Similarly,
here was no significant difference in the number of
reated rejection episodes among the 4 D/R seropairing
roups (data not shown).
iscussion
he present de novo study demonstrated that recipient T.
ondii seropositivity is associated with a significantly in-
reased risk of mortality, primarily reflecting a higher risk of
s (n  288)
pient T. gondii
eronegative
(n  211)
Recipient T. gondii
Seropositive
(n  77) p Value*
14 (7%) 3 (4%) 0.42
2 (1%) 2 (3%) 0.28
5 (2%) 7 (9%) 0.01
8 (4%) 3 (4%) 0.97
4 (2%) 3 (4%) 0.33
9 (4%) 7 (9%) 0.11
9 (4%) 6 (8%) 0.23
ultivariate Predictors of All-Cause Mortalityeyond 1 Y ar After Heart Transplantati n (n  255)
Table 3 Multivariate Predictors of All-Cause MortalityBeyond 1 Year After Heart Transplantation (n  255)
Risk Factor for Mortality Hazard Ratio 95% CI p Value
Recipient age (per incremental year) 1.02 0.99–1.05 0.34
Hypertension 1.32 0.65–2.68 0.44
Current smoker 1.79 0.98–3.26 0.06
Total cholesterol 5.6 mmol/l 1.40 0.77–2.54 0.27
Serum creatinine 118 mol/l 2.01 1.14–3.58 0.02
Recipient T. gondii seropositive 1.93 1.09–3.41 0.02
nly variables with a p value of 0.05 upon univariate Cox analysis were included in the
ultivariate Cox regression model.
CI  confidence interval; T. gondii  Toxoplasma gondii.288)
pient
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November 13, 2007:1967–72 Toxoplasma Seropositivity and Heart TransplantAV-related death. Recipient seropositivity is also a risk
actor for developing more advanced CAV, as shown by
erially performed angiographic examinations. In contrast,
onor seropositivity and D/R seropairing status are not risk
actors for mortality or CAV.
The relationship between recipient T. gondii seropositiv-
ty, reflecting chronic T. gondii infection, and all-cause and
AV mortality may have several explanations. First, chronic
. gondii infection is associated with an enhanced IL-12–
riven IFN- response by T cells, and T-cell–mediated
FN- responses seem to play an important pathogenic role
n CAV (7). It has also been shown that suppression of
FN- correlates well with prevention of CAV (8). Second,
ecent studies suggest that IL-17–producing T helper
ells (TH17) may promote autoimmunity in various
rgans and are implicated in reduced graft survival (9),
nd, notably, T. gondii parasites have been shown to
nduce TH17-mediated responses at least partly involving
L-6 and transforming growth factor -related mecha-
isms (10). Finally, the vascular pathology that underlies
AV appears to be initiated by endothelial cell activation
hat in turn may promote a chronic immune response in
he vessel wall, and with relevance to these data T. gondii
as been shown to enhance endothelial cell activation
hrough IFN-–related mechanisms (11). Although
peculative, we suggest that our findings of a higher risk
f total and in particular of CAV-related mortality in T.
ondii seropositive recipients may be related to changes in
he immunologic milieu in these patients, including an
daptive T-cell response with increased levels of IFN-,
key mediator in the pathogenesis of CAV. However,
hether T. gondii infection is an important trigger of
hese immune responses in HTx will need to be explored
urther with in-depth studies.
The present study has also demonstrated that T. gondii
eropositive recipients are at higher risk of developing
dvanced CAV. This is in concordance with the observed
elationship regarding seropositivity and CAV mortality.
evertheless, intravascular ultrasound would allow a more
etailed assessment of CAV and should be used in future
tudies measuring the inflammatory response in T. gondii
eropositive and seronegative recipients.
ultivariate Predictors of CAV Mortalityeyond 1 Y ar After Heart Transplan tion (n  255)
Table 4 Multivariate Predictors of CAV MortalityBeyond 1 Year After Heart Transplantation (n  255)
Risk Factor for CAV Mortality Hazard Ratio 95% CI p Value
Recipient age (per incremental year) 1.00 0.93–1.07 0.95
Hypertension 2.10 0.38–11.68 0.40
Current smoker 1.25 0.30–5.33 0.76
Total cholesterol 5.6 mmol/l 0.70 0.19–2.57 0.59
Serum creatinine 118 mol/l 1.94 0.51–7.48 0.34
Recipient T. gondii seropositive 4.39 1.26–15.62 0.02
nly variables with a p value of 0.05 upon univariate Cox analysis were included in the
ultivariate Cox regression model.
CAV  cardiac allograft vasculopathy; other abbreviations as in Table 3.onclusions
hese findings suggest that T. gondii seropositivity among
Tx recipients is associated with a significantly increased
isk of all-cause and cardiac mortality as well as the develop-
ent of advanced CAV. The observed higher risk of mortality
nd advanced CAV among seropositive recipients may be
ediated via immunoregulatory changes triggered by
hronic T. gondii infection and needs to be explored further.
eprint requests and correspondence: Dr. Satish Arora, Depart-
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